Company intelligence / Profile preview

Odne

Renens, Vaud, Switzerlandfacebook.com ↗

Ownership: Private
Employees: ~11
Development stage: Preclinical

Overview

Odne has developed and received FDA clearance for the world’s first light-curing injectable hydrophilic endodontic filler ("OdneFill") and its associated curing device ("OdneCure"). These products enable dentists to perform root canal obturations more efficiently by instantly curing the filler inside complex root anatomies. The company’s platform addresses longstanding challenges in root canal treatments such as incomplete filling and reinfection risk. Clinical validation with ISO 13485-produced prototypes has been achieved; commercial launch in the USA began in 2024[6][7][8].

Therapeutic areas: Other
Modalities: DeviceInjectable medical filler
Industry: Surgical Medical Devices

Partnerships

Not specified; collaboration with Swiss Federal Institutes of Technology EPFL & ETH Zürich[1][2][3]

Beyond the preview

Go deeper on Odne.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Odne.

Explore the full profile